• A new artificial intelligence (AI)-powered platform developed to accelerate drug discovery is now available free of charge to eligible global health researchers.
• The tool, dd4gh, has the potential to shorten timelines and reduce costs associated with discovering treatments for diseases that pose significant global health challenges.
• Co-created with global health researchers, dd4gh reflects the needs of scientists tackling diseases such as malaria and tuberculosis, which disproportionately affect people in low- and middle-income countries (LMICs).

‍Geneva, Switzerland & London, United Kingdom — 31 March 2026. Medicines for Malaria Venture (MMV) and deepmirror have launched Drug Design for Global Health (dd4gh), a new open-access, free-to-use AI tool that puts advanced drug discovery tools into the hands of scientists worldwide.

Built to tackle the world’s most pressing global health challenges, dd4gh uses both predictive and generative AI to give researchers, especially those in the most resource-limited settings, access to cutting-edge technology that would otherwise be out of reach.

dd4gh was developed using input gathered during co‑creation workshops in Ghana and Switzerland with global drug discovery researchers. Its AI models are trained on data sets from a wide range of studies conducted by global health researchers, enabling scientists to benefit from insights generated across multiple research efforts.

The platform implements active learning, a technique that allows AI and machine learning (ML) to continuously improve its predictions by learning from new data. It analyses large data sets and proposes the most promising compounds to explore in the lab.

These technologies have the potential to dramatically shorten timelines and reduce costs for drug discovery, allowing scientists to focus their time and resources on what is more likely to work, enabling faster discovery of treatments for diseases that pose significant global health challenges.

The dd4gh tool is available free of charge to eligible researchers working on diseases that primarily affect populations in LMICs such as malaria, tuberculosis and neglected tropical diseases (NTDs). The platform is funded in part by the Gates Foundation, one of MMV’s donors.

Dr Martin Fitchet, Chief Executive Officer of MMV, said: “At a time when the global health sector is facing significant constraints, dd4gh demonstrates the power of partnership. By giving scientists in LMICs free access to advanced AI tools, we can accelerate the discovery of lifesaving medicines – led by the people closest to the diseases we are trying to defeat.”

Democratizing drug discovery forglobal health

The AI revolution has already had a significant impacton drug discovery research, providing scientists with powerful tools that can help them quickly determine which compounds hold the most promise for developing new treatments. Yet, for many researchers in high-burden settings, they remain out of reach due to their high cost.

Caroline Maina, a participant in a co-creation workshop hosted by the University of Ghana and a PhD Candidate at the University of Cape Town, said: “We’re aware of AI tools that can help with drug discovery, but being in a resource-limited setting makes purchasing a license cost prohibitive. Making dd4gh open access for researchers in global health means more of us can explore new ideas and apply AI to finding treatments for diseases that are part of our everyday realities.”

Expanding the availability of these tools will help scientists develop treatments that directly affect their communities while strengthening a more inclusive global scientific ecosystem. “dd4gh reflects our belief that access to advanced AI should not depend on where a scientist works or their laboratory’s resources,” said Dr Max Jakobs, Co-founder and CEO of deepmirror. “Our goal is to enable scientists everywhere to become AI-powered drug discovery experts and accelerate the development of treatments for diseases that affect their communities.”

Researchers working on global health challenges can learn more about dd4gh and apply for access at www.dd4gh.ai.

For press enquiries, contact:
Nicola Hardie
Communications Manager, MMV
Phone +41 79 250 63 38
E-mail: hardien@mmv.org